Back to top
more

Better trading starts here.

Balance Sheet

Research for EVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Evaxion Biotech AS Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 6 13 32 6 10
Receivables 1 1 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 2 3 1 4 1
Total Current Assets 8 17 35 11 11
Net Property & Equipment 4 5 5 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 13 22 40 12 11
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 2 3 3 1
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4 1 1 2 1
Total Current Liabilities 7 4 4 5 2
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 8 8 1 0 0
Non-Current Capital Leases 2 2 2 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 18 14 8 5 2
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 6 4 4 3 2
Capital Surplus 0 0 0 0 0
Retained Earnings -108 -73 -50 -27 -16
Other Equity 97 77 79 32 23
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -5 8 32 7 9
Total Liabilities & Shareholder's Equity 13 22 40 12 11
Total Common Equity -5 8 32 7 9
Shares Outstanding 4.00 2.30 2.20 NA NA
Book Value Per Share -1.18 3.61 14.75 0.00 0.00

Fiscal Year End for Evaxion Biotech AS Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 6 -99,999 7
Receivables NA NA 1 NA 1
Notes Receivable NA NA 0 NA 0
Inventories NA NA 0 NA 0
Other Current Assets NA NA 2 NA 3
Total Current Assets NA NA 8 NA 11
Net Property & Equipment NA NA 4 NA 5
Investments & Advances NA NA 0 NA 0
Other Non-Current Assets NA NA 0 NA 1
Deferred Charges NA NA 0 NA 0
Intangibles NA NA 0 NA 0
Deposits & Other Assets NA NA 0 NA 0
Total Assets NA NA 13 NA 17
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA 0
Accounts Payable NA NA 3 NA 2
Current Portion Long-Term Debt NA NA 0 NA 0
Current Portion Capital Leases NA NA 0 NA 0
Accrued Expenses NA NA 0 NA 0
Income Taxes Payable NA NA 0 NA 0
Other Current Liabilities NA NA 4 NA 2
Total Current Liabilities NA NA 7 NA 4
Mortgages NA NA 0 NA 0
Deferred Taxes/Income NA NA 0 NA 0
Convertible Debt NA NA 0 NA 0
Long-Term Debt NA NA 8 NA 8
Non-Current Capital Leases NA NA 2 NA 2
Other Non-Current Liabilities NA 0 NA 0
Minority Interest (Liabilities) NA NA 0 NA 0
Total Liabilities NA NA 18 NA 14
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA 0
Common Stock (Par) NA NA 6 NA 4
Capital Surplus NA NA 0 NA 0
Retained Earnings NA NA -108 NA -84
Other Equity NA NA 97 NA 82
Treasury Stock NA NA 0 NA 0
Total Shareholder's Equity NA NA -5 NA 3
Total Liabilities & Shareholder's Equity NA NA 13 NA 17
Total Common Equity 0 0 -5 0 3
Shares Outstanding 5.40 5.20 4.00 2.70 2.50
Book Value Per Share 0.00 0.00 -1.18 0.00 1.02